To assess the contribution of
Factor IX/IXa, to intravascular
thrombosis, a canine
coronary thrombosis model was studied.
Thrombus formation was initiated by applying current to a needle in the circumflex coronary artery. When 50% occlusion of the vessel developed, the current was stopped and animals received an intravenous bolus of either saline, bovine glutamyl-glycyl-arginyl-
Factor IXa (IXai), a competitive inhibitor of
Factor IXa assembly into the
intrinsic Factor X activation complex, bovine
Factor IX, or
heparin. Animals receiving saline or
Factor IX developed
coronary occlusion due to a
fibrin/platelet
thrombus in 70 +/- 11 min. In contrast, infusion of IXai prevented
thrombus formation completely (greater than 180 min) at doses of 460 and 300 micrograms/kg, and partially blocked
thrombus formation at 150 micrograms/kg. IXai attenuated the accumulation of 125I-
fibrinogen/
fibrin at the site of the
thrombus by approximately 67% (P less than 0.001) and resulted in approximately 26% decrease in
serotonin release from platelets in coronary sinus (P less than 0.05).
Hemostatic variables in animals receiving IXai, remained within normal limits. Animals given
heparin in a concentration sufficient to prevent occlusive
thrombosis had markedly increased
bleeding, whereas
heparin levels that maintained extravascular hemostasis did not prevent intracoronary
thrombosis. This suggests that
Factor IX/IXa can contribute to
thrombus formation, and that inhibition of IXa participation in the clotting mechanism blocks intravascular
thrombosis without impairing extravascular hemostasis.